Floatz logo

Oxodotreotide

Digestive System Neuroendocrine Neoplasm

National Cancer Institute (NCI)protein_peptidePhase 4 / ApprovedActive
BBB
73/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
62/ 100
Competitive Position
89/ 100

Competitive context

21 Active assets in the Digestive System Neuroendocrine Neoplasm cohort.

Asset / SponsorPhaseRating
L-Cysteinamide, D-Phenylalanyl-L-Cysteinyl-L-Phenylalanyl-D-Tryptophyl-L-Lysyl-L-Threonyl-N-(2-Hydroxy-1-(Hydroxymethyl)Propyl)-, Cyclic (2->7)-Disulfide, (R-(R*,R*))-
Novartis Pharmaceuticals
Phase 3BB
Eudemine Injection
University of Maryland, Baltimore
Phase 4BB
Everolimus
RayzeBio, Inc.
Phase 3BB
Edotreotide
Jiangsu HengRui Medicine Co., Ltd.
Phase 3B
Lanreotide
RayzeBio, Inc.
Phase 3B

View all 31 →

Same molecule, other indications

Oxodotreotide is also rated in:

pancreatic neuroendocrine tumorActive
BBB
Indicative · Phase 4
75 / 100
View asset →
digestive system neuroendocrine tumor, grade 1/2Active
BB
Indicative · Phase 4
69 / 100
View asset →
pancreatic neuroendocrine tumor G1Active
BB
Indicative · Phase 4
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →